Clinical Practice Guidelines (CPG) on EBMonFHIR
1.0.2 - ci-build

Clinical Practice Guidelines (CPG) on EBMonFHIR, published by Universitätsmedizin Greifswald. This guide is not an authorized publication; it is the continuous build for version 1.0.2 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/CEOsys/cpg-on-ebm-on-fhir/ and changes regularly. See the Directory of published versions

Table of Contents

.. 0 Table of Contents
... 1 Clinical Practice Guidelines (CPG) on EBMonFHIR
... 2 Profiles
... 3 Code Systems
... 4 Value Sets
... 5 Extensions
... 6 Examples
... 7 Downloads
... 8 History
... 9 Artifacts Summary
.... 9.1 Cohorts
.... 9.2 CPGComputablePlanDefinition
.... 9.3 CPGRecommendationDefinition
.... 9.4 CPGShareablePlanDefinition
.... 9.5 CPGStrategyDefinition
.... 9.6 Eligibility Criteria
.... 9.7 Outcome Evidence
.... 9.8 PICO Evidence Variable
.... 9.9 Recommendation Action
.... 9.10 Shareable PlanDefinition
.... 9.11 Assessment Action
.... 9.12 Body Positioning Action
.... 9.13 Certainty of Evidence Rating
.... 9.14 Clinical Practice Guideline
.... 9.15 Drug Administration Action
.... 9.16 Evidence Data Set
.... 9.17 Evidence Synthesis Cohorts
.... 9.18 Guideline Bundle
.... 9.19 Guideline Citation
.... 9.20 Intervention Definition
.... 9.21 Net Effect Estimate
.... 9.22 Outcome Definition
.... 9.23 Outcome Evidence Synthesis
.... 9.24 Procedure Action
.... 9.25 Recommendation
.... 9.26 Recommendation Citation
.... 9.27 Recommendation Eligibility Criteria
.... 9.28 Recommendation Justification
.... 9.29 Recommendation Plan
.... 9.30 Study Citation
.... 9.31 Study Cohort
.... 9.32 Study Eligibility Criteria
.... 9.33 Study Outcome Evidence
.... 9.34 Action Combination Method
.... 9.35 ArtifactAssessment Publication Status
.... 9.36 ArtifactAssessment Version
.... 9.37 Characteristic Dosage
.... 9.38 CQFM Artifact Comment
.... 9.39 Dosage Condition
.... 9.40 qualityOfEvidence
.... 9.41 RelativeTime
.... 9.42 strengthOfRecommendation
.... 9.43 Action Combination Method
.... 9.44 Action Selection Behavior Required
.... 9.45 Allergic Disposition SCT
.... 9.46 Assessment
.... 9.47 Assessment Scales
.... 9.48 Body Positioning SNOMED CT
.... 9.49 Clinical Importance of Outcome
.... 9.50 Cochrane PICO
.... 9.51 Cochrane PICO Intervention
.... 9.52 Cochrane PICO Outcome
.... 9.53 Cochrane PICO Population
.... 9.54 Drugs
.... 9.55 Episode Of Care Type
.... 9.56 Guideline Recommendation Status
.... 9.57 Guideline Stage Classification
.... 9.58 Mean Difference Type
.... 9.59 Observations
.... 9.60 Procedures
.... 9.61 Radiologic Finding SCT
.... 9.62 Rating Acceptability
.... 9.63 Rating Benefit And Harms
.... 9.64 Rating Certainty Of Evidence
.... 9.65 Rating Concern Degree
.... 9.66 Rating Consensus
.... 9.67 Rating Equity
.... 9.68 Rating Feasibility
.... 9.69 Rating Preference And Values
.... 9.70 Rating Resources
.... 9.71 Rating Up Rating One Level
.... 9.72 Rating Up Rating Two Levels
.... 9.73 Recommendation Strength
.... 9.74 Relative Effect Type
.... 9.75 Substances SNOMED CT
.... 9.76 VS MII ICU Code Observation Beatmung [LOINC]
.... 9.77 Action Combination Method
.... 9.78 CEOsys Code System
.... 9.79 Clinical Importance of Outcome
.... 9.80 Cochrane Core Ontology
.... 9.81 Cochrane PICO Ontology
.... 9.82 Evidence Certainty Rating
.... 9.83 Evidence To Decision Certainty Rating
.... 9.84 Evidence To Decision Certainty type
.... 9.85 Guideline Stage Classification
.... 9.86 KontaktArtDe
.... 9.87 Recommendation Strength
.... 9.88 SynthesisType
.... 9.89 All-cause mortality
.... 9.90 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) e.V
.... 9.91 Certainty of Evidence for outcome: mortality of Dexamethasone application
.... 9.92 COVID19 Intensive Care Treatment Guideline
.... 9.93 COVID19 Intensive Care Treatment Guideline
.... 9.94 Dexamethasone Application
.... 9.95 Dexamethasone Application
.... 9.96 Dexamethasone Application (Intravenous)
.... 9.97 Dexamethasone Application (Oral)
.... 9.98 Dexamethasone for critically ill COVID-19 patients
.... 9.99 Dexamethasone Recommendation
.... 9.100 Example Assessment Action
.... 9.101 Example Body Positioning Action
.... 9.102 Example Certainty Of Evidence Rating
.... 9.103 Example DrugAdministration Action
.... 9.104 Example Evidence Data Set
.... 9.105 Example Evidence Synthesis Cohorts
.... 9.106 Example Guideline
.... 9.107 Example Guideline Citation
.... 9.108 Example Intervention
.... 9.109 Example Net Effect Estimate
.... 9.110 Example No DrugAdministration Action
.... 9.111 Example Organization
.... 9.112 Example Outcome
.... 9.113 Example Outcome Evidence Synthesis
.... 9.114 Example Procedure Action
.... 9.115 Example Recommendation Citation
.... 9.116 Example Recommendation Eligibility Criteria
.... 9.117 Example Recommendation Eligibility Criteria
.... 9.118 Example Recommendation Eligibility Criteria
.... 9.119 Example Recommendation Justification
.... 9.120 Example Recommendation plan
.... 9.121 Example Study Citation
.... 9.122 Example Study Cohort
.... 9.123 Example Study Eligibility Criteria
.... 9.124 Example Study Outcome Evidence
.... 9.125 Guideline Recommendation Example
.... 9.126 Mortality Outcome for Dexamethasone application
.... 9.127 No Dexamethasone Application
.... 9.128 No dexamethasone application for non-ventilated COVID-19 patients
.... 9.129 NO Dexamethasone for moderately ill COVID-19 patients
.... 9.130 Population: COVID19 Non-Ventilated
.... 9.131 Population: COVID19 Ventilated
.... 9.132 recommendation
.... 9.133 Study cohort for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo)
.... 9.134 Study eligibility criteria for Systemic corticosteroids plus standard care vs. standard care (plus/minus placebo)
.... 9.135 Systemic corticosteroids for the treatment of COVID-19
.... 9.136 Therapy of hospitalized COVID-19 patients